Entrada rises as FDA removes clinical hold on muscle-wasting therapy

Entrada Therapeutics

24/02/2025 13:01

** Shares of drug developer Entrada Therapeutics  TRDA.O 
rise 7.4% to $14 premarket
    ** TRDA says FDA has removed clinical hold on co's therapy,
ENTR-601-44, which is being studied for a type of muscle-wasting
disorder called Duschenne muscular dystrophy (DMD) in the U.S.
    ** Co receives authorization to initiate early-stage trial
    ** In December 2022, the FDA placed a clinical hold on co's
application to start trials of the therapy
    ** Co plans to begin study enrollment in H1 2026
    ** In the last 12 months, TRDA has fallen ~2%


 (Reporting by Siddhi Mahatole)
 ((Siddhiprabhanjan.mahatole@thomsonreuters.com))